-transparent.png){kind=logo}
cis-Dichlorodiammineplatinum(II) (DDP) was studied in 16 children with far-advanced malignancies. Three dosage schedules were tried: regimen A, 20 mg/m2/day x 5 days for 3-4 weeks (11 patients); regimen B, 50 mg/m2 once a week (four patients); and regimen C, 60 mg/m2/day x 2 days every 3-4 weeks (one patient). Four of 16 patients (25%) showed partial response, including one with osteogenic sarcoma, one with neuroblastoma, one with seminoma, and one with medullary carcinoma of the thyroid. Two patients showed clinical improvement. The major toxic manifestations included nausea and vomiting (16 of 16), renal toxicity (three of 16), transient pancytopenia (six of 12), and hearing loss (two of 16). It is apparent that DDP has activity in pediatric tumors; however, a more precise response rate must be delineated in a larger series of patients.
P Kamalakar, and
A I Freeman, and
D J Higby, and
H J Wallace, and
L F Sinks
October 1978,
Cancer treatment reports,
P Kamalakar, and
A I Freeman, and
D J Higby, and
H J Wallace, and
L F Sinks
April 1981,
American journal of obstetrics and gynecology,
P Kamalakar, and
A I Freeman, and
D J Higby, and
H J Wallace, and
L F Sinks
January 1979,
Cancer treatment reports,
P Kamalakar, and
A I Freeman, and
D J Higby, and
H J Wallace, and
L F Sinks
December 1978,
Cancer treatment reports,
P Kamalakar, and
A I Freeman, and
D J Higby, and
H J Wallace, and
L F Sinks
January 1977,
Cancer treatment reports,
P Kamalakar, and
A I Freeman, and
D J Higby, and
H J Wallace, and
L F Sinks
January 1979,
Cancer treatment reports,
P Kamalakar, and
A I Freeman, and
D J Higby, and
H J Wallace, and
L F Sinks
April 1982,
Gan to kagaku ryoho. Cancer & chemotherapy,
P Kamalakar, and
A I Freeman, and
D J Higby, and
H J Wallace, and
L F Sinks
December 1971,
Biochimica et biophysica acta,
P Kamalakar, and
A I Freeman, and
D J Higby, and
H J Wallace, and
L F Sinks
May 1979,
Cancer treatment reports,
P Kamalakar, and
A I Freeman, and
D J Higby, and
H J Wallace, and
L F Sinks
January 1979,
Cancer treatment reports,
